The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

Character Biosciences has raised $93m in an oversubscribed Series B funding round to expedite the progression of precision ...

To apply a precision medicine approach to this disease, Character Bio has partnered with over 150 ophthalmology treatment ...

Jersey City, N.J.-based Character Biosciences has raised $93 million in a series B financing round.  The funding will be used ...

The funding will help fund phase 1 and phase 2 proof-of-concept studies for lead candidates CTX203 and CTX114.

Age-related macular degeneration is a condition that affects individuals over the age of 50. Credit: kazoka/Shutterstock. Character Biosciences has raised $93m in an oversubscribed Series B funding ...

A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...

NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

Funding will enable lead candidates CTX114 and CTX203 for AMD to enter clinical trials in the next year JERSEY CITY, N.J.--(BUSINESS WIRE)--Character Biosciences, a precision medicine company ...

Character Biosciences is entering the clinic with a trove of company-generated human data already in hand. These data inform Character’s approach to targets for the dry form of age-related ...